Announced Wed, 12 Aug · 16:41 IST
Bajaj Healthcare gets DCGI nod to launch Cenobamate API and Tablets in India
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹327.70
prior close
₹330.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.4+1.7+0.9+2.5+0.5-1.4-1.4-3.0-0.6—————
Up moveDown movePending
AI summary
Bajaj Healthcare has received DCGI approval to manufacture and market Cenobamate API and Tablets in six strengths (12.5mg to 200mg), becoming the first company to launch this drug in India. Cenobamate is a next-generation antiseizure medication for partial-onset seizures in adults. The approval strengthens the company Central Nervous System (CNS) portfolio and supports its long-term growth strategy in neurology.
Likely market impact
First-mover advantage in launching an advanced epilepsy drug in India, strengthening the CNS franchise and opening a new growth avenue.